

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
164293	19/YH/0054	258802	(SWHSI 2) A pragmatic, multicentre, randomised controlled trial to assess the clinical and cost effectiveness of negative pressure wound therapy versus usual care for surgical wounds healing by secondary intention	Yes	02/09/2019	10	31	41	07/02/2019	23/07/2019	05/04/2019	24/07/2019	02/08/2019	Please Select...	22/08/2019	D - Sponsor Delays E - Staff availability issues	Sponsor delay with sending full document pack. Some delay at site due to training and number of surgeons involved in trial.	Both
164294	18/NE/0296	248487	CALIBRE Study - CArdioLoL	Yes	10/12/2019	71	27	98	21/05/2019	03/09/2019	19/10/2018	14/11/2019	13/11/2019	Please Select...	14/11/2019	D - Sponsor Delays	Full document pack not	Sponsor

			versus variceal Band ligation in primary pREven tion of variceal bleedin g in liver cirrhosi s														receive d	
164295	19/LO/0 040	253233	EMBRA CE - Apremil ast Phase 4 Study on Quality of life in psoriasi s manifes tations	Yes	14/11/2 019	13	63	76	01/06/2 018	30/08/2 019	19/02/2 019	30/08/2 019	12/09/2 019	Please Select...	04/10/2 019	D - Sponso r Delays E - Staff availabil ity issues	delays in set- up due to pharma cy capacity and also sponsor not complet ing forms for equipm ent. Also SA2 docs received 21/08/2 019. 27/09/2 019 further delays due to sponsor not complet ing forms for equipm ent - sent in Feb 2019	Both

164296	07/HO7 18/57	92703	ITP Registry :United Kingdo m Adult Idiopath ic Thromb ocytope nic Purpura (ITP) Registry : An Investig ation of Disease Progres sion, Treatm ent Effectiv eness, and Co- morbid Conditio ns	Yes	04/11/2 019	14	45	59	23/11/2 018	06/09/2 019	29/01/2 019	20/09/2 019	20/09/2 019	Please Select...	23/09/2 019	E - Staff availabil ity issues	Delays in set up due to R&D Office staff availabil ity (and one full time member of staff retiring)	NHS Provide r
164297	19/SC/0 344	263202	Global SYMPLI CITY Registry	No		36			23/05/2 019	04/12/2 019	26/11/2 019	01/10/2 019	09/01/2 020	Please Select...		A - Permiss ions delayed /denied D - Sponso r Delays	Delay in set up due to HRA approva ls.SIV postpon ed from Nov 2019 due to HRA delay in approva l. Re- booked for Jan'20 due to sponsor availabil ity. 17/01/2 020 still awaiting sponsor green light to open to	Sponso r

																	recruitment. Site selection letter from sponsor was received in May 2019, however the full document pack was not received by R&D Office, therefore site selection date has been entered at 04/12/19. Sponsor had signed CTA in October 2019, with NHS site signing once regulatory approvals received.	
164298	19/NE/0115	255707	SMR-3612 - An Open Label, Multi-Centre, 24 Week,	Yes	12/12/2019	32	48	80	18/10/2018	23/09/2019	03/07/2019	10/10/2019	25/10/2019	Please Select...	28/10/2019	E - Staff availability issues	delay with pharmacy issuing greenlight due to staff	NHS Provider

			Exploratory Study to Assess the Efficacy and Safety of Skilarence? (Dimethyl Fumarate) in Patients with Moderate Plaque Psoriasis														availability	
164299	19/EM/0016	253279	Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA	No		17			10/09/2018	01/11/2019	25/10/2018	12/11/2019	18/11/2019	Please Select...	19/12/2019	B - Suspended by sponsor	suspended recruitment due to COVID pandemic	Sponsor
164300	19/NW/0363	250571	"I4V-MC-JAJA Baricitinib in RA (RA-BRIDGE)"	Yes	18/08/2020	31	249	280	29/03/2019	12/11/2019	08/08/2019	18/11/2019	13/12/2019	Please Select...	13/12/2019	E - Staff availability issues	Staff availability issues to commence trial	NHS Provider
164301	18/SS/0085	243640	Alpha-2 agonists for sedation (A2B Trial)	Yes	05/12/2019	29	27	56	24/10/2018	10/10/2019	14/12/2018	25/11/2019	08/11/2019	Please Select...	25/11/2019	B - Suspended by sponsor	study suspended due to COVID. Re-opened to recruitment on 20/07/2020	Sponsor
164302	18/ES/0119	245233	Stopping Aminos	No					16/11/2018	16/12/2019	09/11/2018			Please Select...		B - Suspended	set-up suspended due	Sponsor

			alicylate Therapy in Inactive Crohn's Disease (STATI C)													ded by sponsor	to COVID.	
164303	19/SC/021	249552	(OPTIM AS Trial) OPTimal TIMing of Anticoa gulation after acute ischaemic Stroke: a randomi sed controll ed trial	Yes	04/02/2020	56	20	76	19/12/2018	20/11/2019	04/04/2019	15/01/2020	15/01/2020	Please Select...	15/01/2020	E - Staff availability issues	PI could not attend planned SIV, date rescheduled to accommodate	NHS Provider
164304	18/YH/0483	237481	BIOSTREAM HF: Observ ation of clinical routine care for heart failure patients implanted with BIOTRONIK CRT devices	Yes	05/03/2020	15	7	22	19/09/2019	12/02/2020	14/10/2019	17/02/2020	27/02/2020	Please Select...	03/03/2020	D - Sponsor Delays	delay with receiving sponsor greenlight to start recruitment.	Sponsor
164305	19/YH/0158	262107	TRANSITION - An open-label, randomi sed, Phase IV study, to assess the	No		42			14/01/2019	16/01/2020	26/07/2019	18/02/2020	27/02/2020	Please Select...	03/03/2020	H - Contracting delays	Following SIV, CTA had to be amended to reduce recruitment target.	Both

			efficacy and safety of tildrakizumab in patients with moderate-to-severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapy															
164306	19/LO/1035	264950	G PLUS - A Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar non-Pustular	No		4			11/01/2019	06/01/2020	29/07/2019	12/12/2019	10/01/2020	Please Select...	20/01/2020	D - Sponsor Delays E - Staff availability issues	December 2019 both CT pharmacists off sick. CRA off sick until 09/01/2020. 17/01/2020 Drs not completed IWRS training so sponsor could not issue green light to commence recruitment. 10/02/2020	Both

			Psoriasis														green light received.	
164307	19/NE/0328	270912	M19-164: A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to risankizumab.	No		0			24/06/2019	05/02/2020	19/11/2019	20/12/2019	05/02/2020	Please Select...	10/02/2020	D - Sponsor Delays E - Staff availability issues	SIV had to be rescheduled from Nov to Jan as approvals not received. Sponsor would not issue green light until Sub-PI in post. 10/02/2020 green light received.	Both